Literature DB >> 33634371

TIGIT promotes CD8+T cells exhaustion and predicts poor prognosis of colorectal cancer.

Rongpu Liang1, Xudong Zhu1, Tianyun Lan2, Dongbing Ding1, Zongheng Zheng1, Tufeng Chen1, Yong Huang1, Jianpei Liu1, Xiaofeng Yang1, Jun Shao1, Hongbo Wei3, Bo Wei4.   

Abstract

TIGIT is a lymphocyte surface receptor, which is mainly expressed on the surface of CD8+T cells. The role of TIGIT in colorectal cancer and its expression pattern in colorectal cancer infiltrating lymphocytes are still controversial. This study aimed at identifying the function of TIGIT in colorectal cancer. Patients with colorectal cancer showed significantly higher TIGIT+CD8+T cell infiltration in tumor tissues, metastases compared with paired PBMC and normal tissues through flow cytometry. TIGIT+CD8+T cells showed an exhausted phenotype and expressed low levels of killer cytokines IFN-γ, IL-2, TNF-α. In addition, more inhibitory receptors such as PD-1, LAG-3, and TIM-3 were expressed on the surface of TIGIT+CD8+T cells. TGF-β1 could promote the expression of TIGIT and inhibit CD8+T cell function in vitro. Moreover, the accumulation of TIGIT+T cells in tumors was associated with advanced disease, predicted early recurrence, and reduced survival rates in colorectal cancer patients. Our results indicate that TIGIT can be a biological marker for the prognosis of colorectal cancer, and TIGIT can be used as a potential target for treatment.

Entities:  

Keywords:  CD8; Colorectal cancer; Exhaustion; TIGIT

Year:  2021        PMID: 33634371     DOI: 10.1007/s00262-021-02886-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

1.  Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Authors:  Harriet M Kluger; Veronica Chiang; Amit Mahajan; Christopher R Zito; Mario Sznol; Thuy Tran; Sarah A Weiss; Justine V Cohen; James Yu; Upendra Hegde; Elizabeth Perrotti; Gail Anderson; Amanda Ralabate; Yuval Kluger; Wei Wei; Sarah B Goldberg; Lucia B Jilaveanu
Journal:  J Clin Oncol       Date:  2018-11-08       Impact factor: 44.544

Review 2.  Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications.

Authors:  Cinzia Solinas; Grazia Pusole; Laura Demurtas; Marco Puzzoni; Roberta Mascia; Gilberto Morgan; Riccardo Giampieri; Mario Scartozzi
Journal:  Crit Rev Oncol Hematol       Date:  2016-11-25       Impact factor: 6.312

Review 3.  Coinhibitory Pathways in Immunotherapy for Cancer.

Authors:  Susanne H Baumeister; Gordon J Freeman; Glenn Dranoff; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2016-02-25       Impact factor: 28.527

Review 4.  Human T Cell Development, Localization, and Function throughout Life.

Authors:  Brahma V Kumar; Thomas J Connors; Donna L Farber
Journal:  Immunity       Date:  2018-02-20       Impact factor: 31.745

Review 5.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

6.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Authors:  Michael J Overman; Sara Lonardi; Ka Yeung Mark Wong; Heinz-Josef Lenz; Fabio Gelsomino; Massimo Aglietta; Michael A Morse; Eric Van Cutsem; Ray McDermott; Andrew Hill; Michael B Sawyer; Alain Hendlisz; Bart Neyns; Magali Svrcek; Rebecca A Moss; Jean-Marie Ledeine; Z Alexander Cao; Shital Kamble; Scott Kopetz; Thierry André
Journal:  J Clin Oncol       Date:  2018-01-20       Impact factor: 44.544

Review 7.  Cancer immunotherapy: harnessing the immune system to battle cancer.

Authors:  Yiping Yang
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 8.  Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.

Authors:  Ryan Gentzler; Richard Hall; Paul R Kunk; Elizabeth Gaughan; Patrick Dillon; Craig L Slingluff; Osama E Rahma
Journal:  Immunotherapy       Date:  2016-05       Impact factor: 4.196

Review 9.  TIGIT as an emerging immune checkpoint.

Authors:  H Harjunpää; C Guillerey
Journal:  Clin Exp Immunol       Date:  2019-12-25       Impact factor: 4.330

Review 10.  Clinical significance of tumor-infiltrating lymphocytes in breast cancer.

Authors:  Sasha E Stanton; Mary L Disis
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751

View more
  13 in total

Review 1.  Update in TIGIT Immune-Checkpoint Role in Cancer.

Authors:  Tiziana Annese; Roberto Tamma; Domenico Ribatti
Journal:  Front Oncol       Date:  2022-05-17       Impact factor: 5.738

2.  Combination Blockade of the IL6R/STAT-3 Axis with TIGIT and Its Impact on the Functional Activity of NK Cells against Prostate Cancer Cells.

Authors:  S González-Ochoa; M C Tellez-Bañuelos; A S Méndez-Clemente; A Bravo-Cuellar; G Hernández Flores; L A Palafox-Mariscal; J Haramati; E J Pedraza-Brindis; K Sánchez-Reyes; P C Ortiz-Lazareno
Journal:  J Immunol Res       Date:  2022-04-12       Impact factor: 4.493

Review 3.  Natural killer cells: a promising immunotherapy for cancer.

Authors:  Junfeng Chu; Fengcai Gao; Meimei Yan; Shuang Zhao; Zheng Yan; Bian Shi; Yanyan Liu
Journal:  J Transl Med       Date:  2022-05-23       Impact factor: 8.440

4.  PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma.

Authors:  Byung-Hyun Lee; Ji-Hea Kim; Ka-Won Kang; Se-Ryeon Lee; Yong Park; Hwa-Jung Sung; Byung-Soo Kim
Journal:  Biomedicines       Date:  2022-05-10

5.  Clinical and molecular assessment of an onco-immune signature with prognostic significance in patients with colorectal cancer.

Authors:  Pankaj Ahluwalia; Ashis K Mondal; Meenakshi Ahluwalia; Nikhil S Sahajpal; Kimya Jones; Yasmeen Jilani; Gagandeep K Gahlay; Amanda Barrett; Vamsi Kota; Amyn M Rojiani; Ravindra Kolhe
Journal:  Cancer Med       Date:  2022-02-09       Impact factor: 4.452

6.  A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.

Authors:  Jie Wen; Xueyi Mao; Quan Cheng; Zhixiong Liu; Fangkun Liu
Journal:  Sci Rep       Date:  2021-11-18       Impact factor: 4.379

7.  Prognostic Role of TIGIT Expression in Patients with Solid Tumors: A Meta-Analysis.

Authors:  Kunmin Xiao; Kunlin Xiao; Kexin Li; Peng Xue; Shijie Zhu
Journal:  J Immunol Res       Date:  2021-11-30       Impact factor: 4.818

Review 8.  Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy.

Authors:  Daijun Wang; Yanmei Gu; Xin Yan; Chengdong Huo; Guan Wang; Yang Zhao; Muzhou Teng; Yumin Li
Journal:  Front Oncol       Date:  2022-03-30       Impact factor: 6.244

9.  The CD226/TIGIT axis is involved in T cell hypo-responsiveness appearance in long-term kidney transplant recipients.

Authors:  Arnaud Del Bello; Anna Gouin; Camille Chaubet; Nassim Kamar; Emmanuel Treiner
Journal:  Sci Rep       Date:  2022-07-12       Impact factor: 4.996

10.  IFN-Gamma Expression in the Tumor Microenvironment and CD8-Positive Tumor-Infiltrating Lymphocytes as Prognostic Markers in Urothelial Cancer Patients Receiving Pembrolizumab.

Authors:  Toru Sakatani; Yuki Kita; Masakazu Fujimoto; Takeshi Sano; Akihiro Hamada; Kenji Nakamura; Hideaki Takada; Takayuki Goto; Atsuro Sawada; Shusuke Akamatsu; Takashi Kobayashi
Journal:  Cancers (Basel)       Date:  2022-01-06       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.